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Summary
 
Kaposi’s sarcoma–associated herpesvirus (KSHV/HHV-8) is a novel human lymphotropic her-
pesvirus linked to several human neoplasms. To date, no animal model for infection by this vi-
rus has been described. We have examined the susceptibility of C.B-17 
 
scid/scid
 
 mice implanted
with human fetal thymus and liver grafts (SCID-hu Thy/Liv mice) to KSHV infection. KSHV
virions were inoculated directly into the implants, and viral DNA and mRNA production was
assayed using real-time quantitative polymerase chain reaction. This revealed a biphasic infec-
tion, with an early phase of lytic replication accompanied and followed by sustained latency.
Ultraviolet irradiation of the inoculum abolished all DNA- and mRNA-derived signals, and
infection was inhibited by ganciclovir. Viral gene expression was most abundant in CD19
 
1
 
 B
lymphocytes, suggesting that this model faithfully mimics the natural tropism of this virus.
Short-term coinfection with HIV-1 did not alter the course of KSHV replication, nor did
KSHV alter levels of HIV-1 p24 during the acute phase of the infection. Although no disease
was evident in infected animals, SCID-hu Thy/Liv mice should allow the detailed study of
KSHV tropism, latency, and drug susceptibility.
Key words: Kaposi’s sarcoma–associated herpesvirus • KSHV • SCID-hu • transmission •
real-time PCR
K
 
aposi’s sarcoma–associated herpesvirus (KSHV),
 
1
 
 also
called human herpesvirus (HHV)-8, is a novel mem-
ber of the lymphotropic human herpesvirus family. KSHV
sequences were identified initially in Kaposi’s sarcoma (KS)
lesions of AIDS patients (1). The virus has also been de-
tected in a variety of AIDS-associated lymphoproliferative
disorders, namely body cavity or primary effusion lymphoma
(PEL; reference 2) and multicentric Castleman’s disease (3).
KS itself is a hyperproliferation of poorly differentiated en-
dothelial cells and is associated with extreme neovascular-
ization. To date, a wealth of epidemiological evidence points
to a central role for KSHV in the development of KS (for
review see references 4–7). For instance, KSHV DNA (8)
and seroreactivity (9) directed against latent or lytic anti-
gens can be detected in virtually all cases of KS. Seroposi-
tivity for KSHV precedes disease and is a major indepen-
dent risk factor for KS in AIDS patients (10–14). Viral
DNA can also be isolated from KS lesions of HIV-1–sero-
negative patients (8), suggesting that KSHV is the principal
viral factor involved in all epidemiological forms of this dis-
ease.
Like all herpesviruses, KSHV has two modes of infection:
lytic replication, which generates infectious progeny and de-
stroys the host cell, and latent replication, in which the viral
genome persists in its host cell but with dramatically re-
stricted gene expression and without cell destruction (15).
Transcripts of latent viral genes (e.g., K12/kaposin, orf73/
LANA, orf72/v-cyclin) are found in most KS tumor cells
(16–19), and a subset of these transcripts (e.g., kaposin and
v-cyclin) may confer a cell-autonomous proliferative advan-
tage to the cells expressing them (20, 21). By contrast,
 
,
 
3% of infected cells in KS lesions or in KSHV
 
1
 
 lymphomas
display evidence of lytic KSHV gene expression (16, 22, 23).
Certain lytic genes (K1, vGCR, vIRF) also transform cultures
of NIH3T3 cells (24–26); however, the relevance of these ob-
servations to tumorigenesis in vivo remains to be established.
A major impediment to the study of KSHV biology has
been the absence of a suitable animal or culture model for
de novo infection. PEL cell lines harbor latent KSHV ge-
nomes and can be induced to produce virions by treatment
 
1
 
Abbreviations used in this paper:
 
 HHV, human herpesvirus; KSHV, Ka-
posi’s sarcoma–associated herpesvirus; PEL, primary effusion lymphoma;
RT, reverse transcriptase.
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with phorbol-12-myristate-13-acetate (TPA) or sodium bu-
tyrate (22). However, most established cell lines or primary
explants support only limited replication or maintenance of
KSHV (27, 28). Unlike its cousin, Epstein-Barr virus (29),
KSHV could not be propagated in SCID mice reconstituted
with human peripheral blood cells (30), and transmission of
KSHV to other conventional laboratory animals has not been
reported. This suggests that the cell type most susceptible
to KSHV replication and latency might be highly special-
ized or not readily propagated ex vivo. To alleviate the prob-
lem of inadequate in vitro systems to study natural infec-
tion, we decided to test whether KSHV could infect cells
in human Thy/Liv organs grafted onto SCID mice.
The SCID-hu Thy/Liv mouse model uses C.B-17 
 
scid/scid
 
mice as recipients of human fetal liver and fetal thymus
implants. Upon coimplantation of both tissues under the
murine kidney capsule, human hematopoietic and lymphoid
precursor cells reconstitute an organ that faithfully repro-
duces human multilineage hematopoiesis, including thymo-
poiesis (31, 32). T lymphocytes in various stages of develop-
ment comprise the bulk (
 
.
 
90%) of cells in the implant, but
cells of all hematopoietic lineages (including monocytes and
B cells) and stromal endothelial cells are present. After direct
injection of virus into the implant, replication of a number of
human viruses is observed in the lymphoid (e.g., HIV-1
[33], HTLV-1 [34], HHV-6 [35], and varicella-zoster virus
[36]) and stromal (e.g., HIV-1 [37], CMV [38], and measles
virus [39]) compartments of the graft. Depending on the bi-
ology of the particular virus, the resulting infection may be
noncytopathic, (e.g., CMV [38]) or may induce severe target
cell depletion (e.g., HIV-1 [40] and HHV-6 [35]).
This paper shows that KSHV derived from cultured PEL
cells can initiate a productive infection in SCID-hu Thy/Liv
mice. Accumulation of viral DNA depends on intact virions
and can be inhibited by ganciclovir. Latent and lytic tran-
scripts can be detected principally in CD19
 
1
 
 lymphocytes,
but the morphology of the implant remains intact and no
cytopathic effects are seen during acute infection. SCID-hu
Thy/Liv mice represent the first animal model in which
KSHV replication and persistence can be observed.
 
Materials and Methods
 
Virus Growth.
 
BCBL-1 cells at a concentration of 5 
 
3 
 
10
 
5
 
cells/ml were induced with 20 ng/ml TPA (Calbiochem) for 12 h,
reseeded in fresh medium (RPMI 1640, 10% FCS, penicillin and
streptomycin, 
 
l
 
-glutamine, sodium bicarbonate, and 
 
b
 
-ME; all
from GIBCO BRL), and cultured for an additional 4 d in 5% CO
 
2
 
at 37
 
8
 
C. This induction protocol results in 
 
z
 
10
 
6
 
 DNA genome
equivalents per milliliter of culture (22). Debris was removed by
centrifugation for 10 min at 5,000 rpm in a GS4 rotor, and virus
was pelleted by centrifugation for 2 h at 14,000 rpm in a SS-38 ro-
tor. Virus from 180 ml supernatant was pelleted, and the pellet was
resuspended in 1,000 
 
m
 
l PBS, of which 50 
 
m
 
l was injected per im-
plant. HIV-1 NL4-3 was prepared as previously described (41).
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SCID-hu Thy/Liv
mice were generated by coimplantation of fragments of human
second trimester fetal liver and thymus under the kidney capsule
of male homozygous C.B-17 
 
scid/scid
 
 (SCID) mice (31). Implants
were infected 4–7 mo after implantation by direct inoculation as
previously described (42). In brief, mice were anesthetized, the
left kidney was surgically exposed, and the implant was inocu-
lated with 50 
 
m
 
l of virus stock. The abdominal wall incision was
sutured, and the skin was closed with staples. Where indicated,
ganciclovir sodium salt (Cytovene; Hoffman-La Roche) was ad-
ministered intraperitoneally twice daily at 50 mg/kg/d from the
day of virus inoculation. At indicated times after inoculation,
mice were killed and their implants surgically removed and pro-
cessed for PCR. For flow cytometry, cell sorting, and quantita-
tive PCR, single-cell suspensions were obtained by grinding the
implants between glass plates. The cells were counted in a Coulter
counter and divided in aliquots for the different assays.
 
PCR and Reverse Transcriptase–PCR.
 
Qualitative reverse tran-
scriptase (RT)-PCR and subsequent Southern hybridization for
lytic messages was performed as described by Renne et al. (27).
Qualitative RT-PCR was performed using the same procedure
with plasmid pDD4 (17) as hybridization probe. A description of
the primers used in these experiments is shown in Table I. In
brief, RNA was isolated using RNAzol (Tel-Test, Inc.) accord-
ing to the supplier’s protocol. 500 ng total RNA was reverse
transcribed using 200 U of Mo-MuLV RT (GIBCO BRL) in a
total volume of 20 
 
m
 
l containing 125 
 
m
 
M dATP, dGTP, and
dTTP, 20 U RNasin (Promega Corp.), and 120 pmol random
hexanucleotide primers (Boehringer Mannheim). After incuba-
tion at 42
 
8
 
C for 35 min, and the reaction was stopped by heating
to 95
 
8
 
C for 5 min, and then 80 
 
m
 
l of a PCR mix containing 10
 
3
 
PCR Mg-Buffer (Perkin-Elmer Corp.), 100 pmol of each
primer, and 5 U of Taq polymerase (Perkin-Elmer Corp.) was
added and amplified over 30 cycles (30 s at 94
 
8
 
C, 1 min at 58
 
8
 
C,
and 1 min 30 s at 72
 
8
 
C).
Quantitative DNA and RT-PCR was carried out in duplicate
using Taqman
 
®
 
 RT and Taqman
 
®
 
 PCR with Amplitaq Gold
 
®
 
reagents (PE Biosystems). Reverse transcription was carried out
using 2.5 
 
m
 
M random hexamers at 25
 
8
 
C for 10 min, 48
 
8
 
C for 30
min, and 95
 
8
 
C for 5 min. PCR was carried out using universal
cycle conditions (2 min at 50
 
8
 
C, 10 min at 95
 
8
 
C, and then 40 cycles
of 15 s at 95
 
8
 
C and 1 min at 60
 
8
 
C) on an ABI PRIZM 7000™
sequence detector (43). To prevent contamination, all PCR reac-
tions were assembled in the segregated space in which neither
KSHV virions nor cloned KSHV DNA was handled. Carryover
of the amplification product was avoided using positive displace-
ment pipettes and UNG glycosylase in the amplification reaction
(44). To determine the sensitivity of the assay, RNA derived
from BCBL-1 cells was used (data not shown). Quantitative anal-
ysis revealed that the signal for the lytic orf29 message was on av-
erage 50–100-fold lower than the signal for spliced latent mes-
sages in latently infected BCBL-1 cells, consistent with prior
observations (22) that only 1–5% of BCBL-1 cells undergo spon-
taneous KSHV replication at any given time. The assay was lin-
early dependent on input cell number in the range of 1–10
 
5
 
 in-
fected cells per reaction). We found that KSHV could be most
sensitively detected using primers that detect both spliced and
nonspliced latent transcripts (primers lat-273F, lat-335R, and lat-
294T; see Table I). With such primers, we were consistently able
to detect 1 infected cell in 10
 
5
 
 uninfected cells.
 
Cell Sorting and Flow Cytometry.
 
Single-cell suspensions were
incubated with biotinylated mAbs directed against human CD4,
CD8, and CD3–biotin (all from Becton Dickinson) for 0.5 h in
PBS and 2% FBS on ice and depleted using Dynabeads (Dynal
Inc.) according to recommendations from the manufacturer. Pre-
and postdepletion cell populations were stained with streptavidin–
FITC and PE-conjugated mAbs directed against human CD19
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(Becton Dickinson) and separated on a FACSVantage™ (Becton
Dickinson) cell sorter to isolate CD19
 
1
 
 B cells, CD4
 
1
 
, CD8
 
1
 
, and
CD3
 
1
 
 T cells, and cells negative for all four markers. Sort-purified
cells were frozen as pellets and stored at 
 
2
 
80
 
8
 
C before processing.
 
Results
 
Replication of KSHV in Human Thy/Liv Implants.
 
To test
whether KSHV would replicate in the human Thy/Liv im-
plants of SCID-hu mice, we prepared concentrated KSHV
virions from induced BCBL-1 cell supernatant (22) and in-
oculated 50 
 
m
 
l of virus suspension (containing 
 
z
 
10
 
7
 
 genome
equivalents) directly into each implant, according to estab-
lished procedures (32). As an average implant contains
 
z
 
10
 
8
 
 human cells, the maximal multiplicity of infection is
an estimated 0.1 genome equivalents per cell. However, it
is likely that this substantially overestimates the true multi-
plicity of infection, because it is unlikely that all of the in-
put virions are infectious (in many viruses, the particle/pfu
ratio can be as high as 10
 
2
 
–10
 
4
 
). Each cohort included ani-
mals injected with UV-inactivated KSHV to serve as nega-
tive control; UV irradiation should completely abolish in-
fectivity by cross-linking the double-stranded DNA genome
(45–47). At various times after inoculation, the mice were
killed. To have all cell types represented, the implants were
removed in toto, and 2.5 
 
m
 
g of total implant DNA (corre-
sponding to 
 
z
 
4.5 
 
3 
 
10
 
5
 
 cells) was assayed for the presence
of viral DNA by quantitative real-time DNA PCR using
 
Table I.
 
Primers Used for Detection of Latent and Lytic Transcripts
 
Latent RT-PCR
#7209 (23mer) 5
 
9
 
-GCATATGCGAAGTAAGAGATTGT
#7307 (21mer) 5
 
9
 
-AGCAGCAGCTTGGTCCGGCTG
#7322 (24mer) 5
 
9
 
-GGTCCTGGGGACTCTCCACAGGAA
#7324 (25mer) 5
 
9
 
-AGCAGCTTGGTCCGGCTGACTTATA
orf29 RT-PCR
#290A (19mer) 5
 
9
 
-GCAGCTAGCCAACTCCGTG
#290B (19mer) 5
 
9
 
-GCAGGAAACTCGTGGAGCG
GAPDH control
gapdh-a (24mer) 5
 
9
 
-CCACCCATGGCAAATTCCATGGCA
gapdh-s (24mer) 5
 
9
 
-TCTAGACGGCAGGTCAGGTCCACC
Real-time quantitative RT-PCR for spliced lytic orf29
tac29-5F (16mer) 5
 
9
 
-CCCGGAGGACGGTCCA
tac29-68R (21mer) 5
 
9
 
-CCCCGAATGCTCTGTTCTTATT
tac29-22T (23mer) 5
 
9
 
-Fam-CTCGCTGATGTGCGCAACATGCT-Tamra
Real-time quantitative RT-PCR for unspliced latent orf73
lat-273F (20mer) 5
 
9
 
-ACTGAACACACGGACAACGG
lat-335R (19mer) 5
 
9
 
-CAGGTTCTCCCATCGACGA
lat-294T (22mer) 5
 
9
 
-Fam-TAGCGTACTCTCGCGGCCCAGC-Tamra
Real-time quantitative RT-PCR for spliced latent orf72
lat-335R (19mer) 5
 
9
 
-CAGGTTCTCCCATCGACGA
TAQ-F1 (21mer) 5
 
9
 
-AGGCAGCTGCGCCACGAAGCA
lat-294T (22mer) 5
 
9
 
-Fam-TAGCGTACTCTCGCGGCCCAGC-Tamra
Ribosomal RNA
riboF (20mer) 5
 
9
 
-CGGCTACCACATCCAAGGAA
riboR (18mer) 5
 
9
 
-GCTGGAATTACCGCGGCT
riboP (22mer) 5
 
9
 
-Joe-TGCTGGCACCAGACTTGCCCTC-Tamra
myc
c-mycF (20mer) 5
 
9
 
-TCAAGAGGTGCCACGTCTCC
c-mycR (22mer) 5
 
9
 
-TCTTGGCAGCAGGATAGTCCTT
c-mycP (23mer) 5
 
9
 
-Fam-CAGCACAACTACGCAGCGCCTCC-Tamra
 1860
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primers lat-273F, lat-335R, and lat-294T (Table I). Fig. 1 A
shows a standard curve for the real-time quantitative DNA
PCR to demonstrate the linear range of the assay, and Fig.
1 B shows a time course of infection. KSHV-specific DNA
was low or undetectable in most implants 7 d after inocula-
tion, peaked with a mean signal of 
 
z
 
100 times background
at day 14, and then receded to lower levels at days 21 and
28. This increase in KSHV genome copy number between
days 7 and 14 after inoculation and subsequent reduction
provides evidence for initial viral replication in the implant,
as would be expected in a de novo infection. Exposure of
KSHV virions to UV irradiation blocked infectivity.
Assuming that, as in cultured PEL cell lines, infected cells
harbor 
 
z
 
50 copies of episomal KSHV DNA per cell, we
estimate that this level of viral DNA would correspond to
infection of 
 
z
 
1 cell in 1,000 in the implant (see Fig. 7). As
CD19
 
1
 
 B cells represent between 0.2 and 2% of the total
number of cells in the implant (31), the actual density of in-
fection in this permissive subpopulation is likely to be higher.
No difference in the levels of KSHV-specific DNA or
transcripts was found between implants derived from dif-
ferent fetal sources (
 
n
 
 5 
 
4), indicating that susceptibility to
KSHV infection is independent of the donor background.
 
RT-PCR for KSHV mRNAs Allows the Identification of
Latent and Lytic Infection.
 
Lytic herpesvirus replication pro-
ceeds in a regulated cascade of differential gene expression.
Late lytic gene transcription in particular is dependent on
viral replication and an array of viral transacting factors,
whereas latent gene transcription occurs in the absence of
lytic viral transactivators. If the initial increase in viral DNA
noted in the SCID-hu Thy/Liv implants was indeed due to
bona fide lytic replication, it should have been accompa-
nied by late lytic gene transcription. Therefore, evidence
for mRNA from orf29, a well characterized late viral gene
product whose production occurs only in cells undergoing
viral replication, was sought by RT-PCR. Following our
previously established protocol (27), total implant RNA
was isolated, reverse transcribed using random hexamers, and
amplified using primers specific for lytic messages (primers
290A and 290B; Table I). Amplified products were sepa-
rated on a 2% agarose gel and hybridized with 
 
32
 
P-labeled
probes specific for either product. In this assay, a cutoff was
established, and only implants yielding detectable amplifi-
cation products were scored positive. Primers for the am-
plification of the lytic orf29 message were located on oppo-
site sides of intron #1; hence, amplification products of the
proper size can derive only from late messages and not from
contaminating viral DNA.
We also developed similar qualitative techniques to de-
tect evidence for latent transcription (Fig. 2), using primers
specific for either the latent nonspliced orf73 message or
spliced orf72 message (primers #7209, #7307, and #7324;
Table I). As for orf29, correct amplification products using
orf72-specific primers can only derive from properly pro-
cessed mRNA. Amplification products with orf73 primers
could derive from either DNA or RNA; however, we esti-
mate that .90% of the signal is derived from amplification
of mRNA. Fig. 2 shows the location of the primers and the
result of a control amplification from BCBL-1 RNA. Lanes
7–9 show evidence of latent message as judged by the pres-
ence of amplification products of the expected size (Fig. 2 B).
Using primers specific for spliced orf72 message, no signal
was generated in the absence of RT (compare lanes 7 and 8
to 4 and 5). Using primers for unspliced orf73 message, a
faint band was detected in the absence of RT, presumably
resulting from residual viral DNA (lane 6), but was strongly
augmented in the presence of RT (lane 9).
Using the RT-PCR assays outlined above, evidence for
productive KSHV infection could be detected in human
Thy/Liv implants injected with KSHV (Table II). At day
14 after inoculation, KSHV-latent transcripts were detect-
able in all infected implants but not in any of the implants
Figure 1. (A) Standard curve for quantitation of DNA copy number. The vertical axis shows copies of target DNA per reaction. The horizontal axis
shows the ct values as determined by real-time quantitative PCR. (B) Time course of infection. Implants are measured in duplicates (except at day 28).
Each mark (s) shows the copy number (logarithmic scale) per 2.5 mg of total implant DNA. The horizontal axis shows times after inoculation. The col-
umn labeled UV presents the signal obtained from implants that received UV-inactivated virus. The median of each group is indicated by the dashed line.
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that were injected with UV-inactivated KSHV (P # 0.005
by X2). Human GAPDH (glyceraldehyde-3-phosphate-
dehydrogenase)-specific message could be amplified in each
case. This demonstrates that infection was dependent on
intact, functional virions. Up to 50% of implants harbored
levels of lytic transcripts above the cutoff detectable in this
assay (P # 0.1 by X2), suggesting that lytic KSHV replica-
tion was supported in these instances (summarized in Table
II). To demonstrate that these results were not specific to the
BCBL-1 isolate of KSHV, the experiments were repeated
with KSHV purified from the equivalent number of in-
duced BC-3 cells (data not shown). As in previous experi-
ments, KSHV latency–specific messages could be amplified
from all implants injected with BC-3–derived KSHV but
not from those injected with UV-inactivated virus. These
results establish that both PEL-derived isolates are func-
tional in this assay.
We next determined the time course of latent and lytic
gene transcription. Latent transcripts were detectable in al-
most all animals (seven to eight of eight) up to 4 wk after
inoculation and in two of four animals 16 wk after inocula-
tion. Moreover, one of two infected mice showed evi-
dence of latent transcripts 6 mo after inoculation. However,
the fraction of implants with detectable lytic transcripts peaked
at day 14 and then declined (Fig. 3). The peak of lytic gene
transcription coincided with the peak of viral DNA load (as
reported in Fig. 1), supporting the hypothesis that the in-
crease in genome copy number resulted from authentic vi-
ral replication. Furthermore, no lytic transcripts were detected
21 d after inoculation, suggesting that productive infection
was dramatically diminished or had ceased by that time. As
before, UV inactivation of the virus abolished both latent
and lytic signals.
In the SCID-hu Thy/Liv model, human B cells do not
migrate outside the implant. Consistent with this observa-
tion, no KSHV-specific signal could be detected in the spleens
of infected animals (data not shown), suggesting that the
infection was species specific and did not spread to murine
tissue.
Ganciclovir Interferes with Establishment and Maintenance of
Infection. As ganciclovir inhibits KSHV replication in vitro
(48, 49), we investigated whether the drug would also in-
hibit KSHV infection in the SCID-hu Thy/Liv model. Six
infected animals were treated with twice-daily intraperito-
neal injection of 50 mg/kg/d ganciclovir beginning at the
time of KSHV inoculation. To concentrate our analysis
specifically on productively infected cells, we quantitatively
analyzed spliced transcript levels rather than viral DNA.
ABI Taqman® technology was used for real-time quanti-
tative RT-PCR analysis (43). RNA was prepared and am-
plified in duplicate using primers specific for either spliced
lytic (primers tac29-5F, tac29-68R, and tac29-22T) or spliced
latent messages (primer lat-273F or TAQ-F1 with lat-
335R and lat-294T; Table I and Fig. 4). Primers for ampli-
fication of the lytic orf29 message were located on opposite
sites of intron #1, and the fluorescently labeled oligonucle-
otide probe spanned the splice junction. Hence, only cor-
rectly spliced late messages for orf29 were detected (Fig. 4 B).
For the amplification of latent messages, primers specific
for the spliced orf72 message were used (Fig. 4 A). As these
primers differed in sequence from those employed for qual-
Figure 2. Primer design and control reaction
for the detection of latent messages. (A) The sche-
matic outlines the genomic organization and mes-
sage structure as determined previously (17). Ar-
rows indicate a given primer identified by its
number. SD and SA denote the splice donor and
splice acceptor sites, respectively. 71, 72, and 73
refer to the latent orfs of KSHV. (B) The autorad-
iograph of a Southern hybridization of an RT-
PCR reaction using forward primer #7209 and
the different primers indicated directly above each
lane, which were then hybridized with a latency-
specific probe. The reactions used BCBL-1–derived
RNA in either the absence (RT2) or presence
(RT1) of RT or with no template (water). MW,
100-bp molecular mass markers with the hybrid-
ized marker.
Table II. KSHV Transcript Analysis of Infected Implants
Experi-
ment Time Virus
RT-PCR
gapdh Latent Lytic
d
1 14 BCBL-1 7/7 7/7 2/7
14 BCBL-1 and UV 3/3 0/3 0/3
P # 0.005 P # 0.3
2 14 BCBL-1 8/8 8/8 4/8
14 BCBL-1 and UV 3/3 0/4 0/4
P # 0.005 P # 0.1
The results and statistical analysis of the qualitative RT-PCR assay for
glyceraldehyde-3-phosphate-dehydrogenase (gapdh) and lytic (orf29) or
latent (orf73) mRNA for two independent experiments of implants in-
fected with KSHV derived from BCBL-1 cells or UV-inactivated virus.
Shown is the number of positive implants per total number of analyzed
implants. P values were calculated using X2 statistics.
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itative RT-PCR, RNA from each implant was analyzed
twice for each transcript (qualitatively and quantitatively)
using two different primer pairs. Implants that yielded
significant signal using real-time quantitative RT-PCR
always scored positive in the qualitative PCR, and samples
that did not result in an amplified product using the quali-
tative RT-PCR and radioactive hybridization never showed
a signal using real-time quantitative PCR and fluorescent
detection. Only a single amplification product was pro-
duced in the quantitative RT-PCR reaction (data not shown).
The amount of product was quantified at each cycle using a
third specific, fluorescently labeled oligonucleotide present
during the reaction. Hence, the number of cycles (ct) needed
for the fluorescence intensity to reach a threshold value is a
direct measure of the amount of amplified product. Based
on control reactions using RNA from latently infected
BCBL-1 cells, sensitivity limits were established to be 1–10
cells per reaction for the spliced latent orf72 assay and 100–
1,000 cells per reaction for the lytic orf29 assays (Fig. 4, C
and D), consistent with the observation that ,3% of the
population undergoes spontaneous lytic reactivation at any
given time and the levels of orf29 mRNA in this popula-
tion are much lower. The assay was linearly dependent on
input RNA over three orders of magnitude.
Fig. 5 shows relative transcript levels in infected implants
at day 14 after inoculation. Total RNA was isolated from
individual implants in each group (implants injected with
KSHV, implants injected with UV-inactivated KSHV, and
implants injected with KSHV and treated with ganciclovir)
and assayed in duplicate. To normalize for the amount of
Figure 3. Time course of infection as determined by
RT-PCR for the presence of latent (filled bars) or lytic
(hatched bars) messages. Depicted is the percentage of im-
plants giving a positive RT-PCR signal at indicated days af-
ter inoculation; n denotes the number of mice analyzed at
each time point. The column with UV represents the signal
obtained from implants that received UV-inactivated virus.
Figure 4. Primer design for quantitative
RT-PCR. (A) The schematic outlines the
genomic organization and message structure
for orfs 71, 72, and 73 as determined previ-
ously (17). Arrows indicate given primers.
(B) The schematic outlines the genomic or-
ganization and message structure of orf29 as
determined previously (27). Arrows indicate
given primers. C and D show detection lev-
els for latent (C, d) and lytic (D, r) probes
compared with c-myc (h). The number of
latent BCBL-1 cells per reaction is shown on
the vertical axis, and the corresponding ct
value as determined by real-time quantitative
RT-PCR is shown on the horizontal axis.
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RNA in each reaction, rRNA was coamplified and quanti-
fied using a differently labeled probe (primers riboF, riboR,
and riboP; Table I). Ct values for KSHV-specific probes
were subtracted from corresponding Ct values for rRNA
and expressed as the number of latent or lytic cells per 106
cells (based on BCBL-1 control). As expected, implants in-
jected with live virus exhibited significant levels of spliced
latent (P , 0.005) and lytic (P , 0.01) transcripts com-
pared with implants injected with UV-inactivated virus.
Many animals displayed transcript levels that would corre-
spond to 1 infected cell in 1,000 (assuming that transcript
levels per cell are similar to those in BCBL-1 cells). Ani-
mals treated with ganciclovir showed a reduction in both
latent (P , 0.1) and lytic (P , 0.05) transcript levels com-
pared with untreated implants. RNA derived from latent
BCBL-1 cells served as positive control. These data suggest
that ganciclovir affected both the initial replication and sub-
sequent spread of KSHV as well as establishment of latent
infection, resulting in a decrease for both messages.
Productive KSHV Infection Occurs Predominantly in CD191
B Cells. To determine the cell tropism of KSHV in the
Thy/Liv organ, we purified relevant cell populations from
infected implants using flow cytometry and examined them
for the presence of KSHV-specific transcripts (Fig. 6). B cells
were identified by staining with anti-CD19–PE antibodies
and T cells by staining with a mixture of FITC-coupled anti-
CD4, anti-CD8, and anti-CD3 antibodies. As reported
previously (31), an average of 0.5–2.5% of all cells in the
implant were committed to the B cell lineage, as indicated
by CD19 expression, whereas .90% of the implant cells
were thymocytes, as indicated by CD3 expression (Fig. 6 A,
implant). A fraction of the implant was used to isolate 106
CD31 thymocytes directly using flow cytometry. The re-
mainder of the implant was depleted of thymocytes using
biotinylated anti-CD3 and anti-CD8 antibodies coupled to
Figure 5. Analysis of transcript levels in infected implants. A and B
show latent and lytic transcript levels expressed as the number of latent or
lytic cells per 106 cells (logarithmic scale) for implants at day 14 after inoc-
ulation that were infected with KSHV (KSHV), infected with KSHV and
treated with ganciclovir (KSHV ganc.), or infected with UV-inactivated
virus (KSHV UV); BCBL-1 cells are shown as control. The median of
each group is indicated by the dashed line. P values were calculated using
the nonparametric Mann-Whitney test.
Figure 6. Tissue tropism of KSHV in infected SCID-hu Thy/Liv
mice. (A) Representative FACScan™ analysis for CD19 (vertical) or
combined CD41, CD81, and CD31 (horizontal) in cells pooled from
three KSHV-infected implants harvested 14 d after inoculation: before T
cell depletion (implant), after T cell depletion (depleted), or after sorting
for CD191 cells of the depleted cell population (sorted). The total num-
ber of cells in the sample is also indicated. The percentage of CD19–PE
or CD4–, CD8–, CD3–FITC1 cells is shown in the upper left and lower
right quadrants, respectively. B shows the levels of KSHV-specific latent/
orf73 (filled bar) or lytic (hatched bar) transcripts in the indicated cell
populations. All samples were assayed in duplicate and normalized for
rRNA content. Standard deviations were too small to be visible on this
scale. Levels are expressed as fold background (logarithmic scale) from un-
infected CD19 cells.
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streptavidin-linked magnetic beads (Fig. 6 A, depleted). The
depleted population was stained with CD19–PE and avidin–
FITC, and CD19 single-positive cells were isolated by flow
cytometry. Although only 40,000 CD191 cells could be ob-
tained for analysis, KSHV-specific latent and lytic transcripts
could be detected in this cell population. This is consistent
with previous observations, which detected KSHV in pe-
ripheral blood CD191 B cells (27, 47, 50). Low levels of
KSHV-specific latent but never lytic transcripts were also
detected in the cells negative for CD3, CD4, CD8, and
CD19. We would expect to find stromal cells and macro-
phages in this population, which harbors KSHV in KS tu-
mors (51). Experiments to determine the exact nature of
these cells as well as the level of KSHV gene expression in
them are currently underway. Even lower levels of latent
transcript were detected in cells positive for CD3, i.e., T
cells. Although we cannot exclude the possibility that the
signal originates from contaminating B cells, reanalysis of the
sorted CD3, CD4, and CD8 fractions determined them to
be $99% CD31 (data not shown).
Histological (hematoxylin and eosin stain) and flow cyto-
metric analysis (using mAbs directed against CD19, CD20,
and CD45) showed no evidence of B cell depletion during
the first 4 wk of infection. During this time frame, in fact,
KSHV infection of the Thy/Liv implant was not correlated
with any histopathologic changes (data not shown). We are
currently following a cohort of infected mice to assess long-
term consequences of infection.
Coinfection of SCID-hu Thy/Liv Mice with HIV-1 and
KSHV. To test whether an interaction between KSHV
and HIV-1 might occur in coinfected implants, cohorts of
SCID-hu Thy/Liv mice were injected with a mixture of
HIV-1 and KSHV or with each virus alone. The patho-
genic, syncytium-inducing HIV-1 isolate NL4-3 was used
at an input inoculum of 103 tissue culture (TC)ID50. This
strain induces massive T cell depletion starting at day 14 af-
ter inoculation, with ,85% of implant thymocytes being
destroyed by day 28–35 (42). Accordingly, we chose to ex-
amine the coinfected implants on day 14, when HIV-1 in-
fection is well established but before the onset of T cell
death complicates the analysis of effects on viral load. KSHV
viral load and HIV-1 p24 and RNA levels were quantitated
at this time point (Fig. 7). Relative to animals infected with
KSHV alone, no difference was noted in the levels of KSHV
DNA in animals coinfected with HIV-1 and KSHV. The
mean KSHV-specific DNA PCR signal in these two cohorts
Figure 7. HIV-1 and KSHV viral load in coinfected ani-
mals. (A) KSHV genome copy number (s) per 200,000 cells
in implants infected with KSHV, HIV-1, HIV-1, and KSHV
or UV-inactivated KSHV and HIV-1. The right side depicts a
standard curve for dilution series of pDD4 and the corre-
sponding fluorescent threshold (ct). Dashed line indicates the
lower limit of detection in this assay. (B) HIV-1 p24 levels in
pg per 106 cells (s) in implants 14 d after inoculation infected
with KSHV, HIV-1, HIV-1, and KSHV or UV-inactivated
KSHV and HIV-1 (mock).
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was 10–100 times the signal obtained from animals infected
with UV-inactivated virus or HIV-1 alone, suggesting that
KSHV replicated as in previous experiments and that its
level of replication was unaffected by HIV-1. Correspond-
ingly, the level of HIV-1 p24 in the implant was reduced
only minimally in animals coinfected with KSHV as com-
pared with animals infected with HIV-1 alone. We con-
clude that KSHV did not significantly influence HIV-1
replication, at least in the short period of acute coinfection.
Discussion
The absence of an appropriate animal model to study de
novo infection has severely limited our understanding of
the biology of KSHV. This paper reports the first small an-
imal model for de novo infection by KSHV. It demon-
strates that BCBL-1–derived KSHV preparations can infect
SCID-hu Thy/Liv mice, resulting in transient lytic replica-
tion and persistent latent infection, as judged by (a) the in-
crease in genome copy number and (b) the presence of la-
tent and lytic viral transcripts in infected animals.
Flow cytometric analysis demonstrates that KSHV repli-
cates primarily in CD191 B cell populations of the implant,
which is consistent with the tropism described for KSHV in
humans (47, 51–53). As KSHV does not replicate in SCID
mice (30) that have received human peripheral blood leu-
kocytes (a model that does not support hematopoiesis; ref-
erence 29), our observations suggest that immature or de-
veloping cell populations may serve as the predominant
target of KSHV infection. Alternatively, it is possible that
transmission to human blood cells requires a lymphoid mi-
croenvironment not reproduced by the implant. Dissecting
the tissue tropism of KSHV in detail and mapping KSHV
gene expression in different host cells will be one of the
major uses of the SCID-hu Thy/Liv system.
The presence of lytic replication during the early phase
of infection suggests another potential application of this
model: to assess the impact of antivirals and biological re-
sponse modifiers on KSHV replication in vivo, similar to
its established use in the development of anti-HIV drugs.
The susceptibility of KSHV infection to ganciclovir in vivo
faithfully mirrors prior in vitro findings and affirms that this
model, once optimized, may become a useful part of pre-
clinical drug development.
Coinfection with HIV-1 did not enhance or interfere
with KSHV replication, and the presence of KSHV did not
influence the replication kinetics or cytopathogenicity in-
duced by HIV-1. KSHV encodes viral chemokines that block
interactions between HIV-1 and CCR5/CCR3 in vitro
(54–56), raising the speculation that this mechanism might
also be operational in vivo (for review see reference 57).
The absence of a significant effect of KSHV on HIV-1 rep-
lication argues against this, although the small number of
KSHV-infected cells in the implant does not allow us to
entirely exclude the possibility of interactions in vivo. HIV-1
itself is known to induce a number of cytokines (IFN-g,
TNF-a, IL-1, and IL-6), and these as well as HIV-1 Tat it-
self have been proposed to be involved in the development
of KS (for review see reference 58). Although analogous
changes in cytokine expression may occur in HIV-1–infected
SCID-hu Thy/Liv implants compared with infected PBMCs,
no effect of HIV-1 on KSHV replication was observed,
suggesting that HIV-1–induced cofactors did not have an
impact on KSHV replication in this context. Ongoing ex-
periments are now testing the possibility that interactions
between HIV-1 and KSHV might be observed after coin-
fection with different isolates of HIV-1 and/or after longer
periods of time.
KSHV infection of the Thy/Liv implant did not produce
detectable histological phenotypes reminiscent of known
KSHV-related human diseases. Certainly the model was
not expected to reproduce KS, a neoplasm involving poorly
understood cells of endothelial lineage (5). Although some
CD341 cells are doubtless present in the implant, it is un-
likely that the full range of endothelial precursors, stromal
components, and growth factors needed to support KS de-
velopment would be present in this system. Rather, the
model was designed to examine infection of the lymphoid
compartment. The model successfully produces transient
lytic infection and more sustained viral persistence and appears
to mirror the correct tissue tropism of infection. However,
it did not give evidence for lymphoid depletion or lym-
phoproliferation. Although the small number of B cells
present in the implant severely constrained our ability to
score for B cell depletion, the proportion of CD191 cells
did not appear to diminish over time. Similarly, we did not
observe expansion of the B cell population and did not de-
tect features reminiscent of Castleman’s disease or PEL. How-
ever, it is important to remember that both of these pheno-
types are exceedingly rare manifestations of human KSHV
infection. Judging from the fact that z5–7% of healthy
subjects are KSHV seropositive, it is likely that most primary
infections with this agent are subclinical or asymptomatic.
Thus, it is not clear that the relatively bland histologic pic-
ture generated here is not representative of many human
primary infections. We are continuing to study the model
to see if disease appears at late times after inoculation or if the
system can be experimentally modified to allow induction of
cell injury or proliferation. In the meantime, in addition to its
potential uses in drug screening, the model offers an excellent
opportunity to better define in detail which subsets of CD191
cells are most permissive for KSHV and whether and how ef-
ficiently T cells and macrophages can be targets of infection.
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